Anti-Müllerian Hormone Protein Expression Is Reduced during the Initial Stages of Follicle Development in Human Polycystic Ovaries
Sharron A. Stubbs,
Kate Hardy,
Patricia Da Silva-Buttkus,
Jaroslav Stark,
Lisa J. Webber,
Adrienne M. Flanagan,
Axel P. N. Themmen,
Jenny A. Visser,
Nigel P. Groome and
Stephen Franks
Institute of Reproductive and Developmental Biology (S.A.S., K.H., P.D.S.-B., L.J.W., S.F.), Wolfson and Weston Research Centre for Family Health, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom; Department of Mathematics (J.S.), Imperial College London, London SW7 2AZ, United Kingdom; Histopathology Department (A.M.F.), Division of Investigative Sciences, Imperial College London, St. Marys Hospital, London W2 1PG, United Kingdom; Department of Internal Medicine (A.P.N.T., J.A.V.), Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands; and School of Biological and Molecular Sciences (N.P.G.), Oxford Brookes University, Headington Campus, Oxford OX3 0BP, United Kingdom
Address all correspondence and requests for reprints to: Kate Hardy, Institute of Reproductive and Developmental Biology, Wolfson and Weston Research Centre for Family Health, Imperial College London, Hammersmith Hospital, London W12 0NN, United Kingdom. E-mail: k.hardy{at}imperial.ac.uk.
Context: Polycystic ovary syndrome, the most common cause ofanovulatory infertility, is characterized by disordered folliculogenesis,notably increased progression from the primordial to the primarystages. This ovarian phenotype is similar to that observed inmice lacking anti-müllerian hormone (AMH).
Objective: The objective of this study is to investigate whetherAMH is involved in accelerating the transition of folliclesfrom primordial to primary stages in polycystic ovaries.
Design: This study compares AMH expression in archive tissuefrom normal and polycystic ovaries.
Setting: This is a laboratory-based study.
Patients: Ovarian tissue from seven normoovulatory women and16 women with polycystic ovaries (five of whom were anovulatory)was used in this study. Ovaries were classified by histologyand with reference to menstrual cycle history and ultrasound.
Main Outcome Measure: Presence and intensity of AMH expressionin 1403 follicles was the main outcome measure.
Results: AMH was observed from the primordial stage onward.AMH immunostaining was observed in significantly fewer primordial(P = 0.007) and transitional follicles (P = 0.001) in ovariesfrom anovulatory women with polycystic ovaries compared withwomen with regular cycles and either normal or polycystic ovaries.AMH-negative follicles had fewer pregranulosa cells in the largestcross-section of the follicle at both the primordial (median,four and six for AMH-negative and -positive follicles, respectively;P < 0.0001) and transitional stages (median six and nine;P < 0.0007) in normal tissue, and fewer at the transitionalstage (median, seven and 11; P < 0.0001) in tissue from anovulatorywomen with polycystic ovaries. This suggests that AMH expressionis associated with granulosa cell mitosis.
Conclusions: These findings indicate a relative deficiency ofAMH in primordial and transitional follicles in ovaries fromanovulatory women with polycystic ovaries. This may contributeto disordered early follicle development in polycystic ovarysyndrome.
This article has been cited by other articles:
L. G. Nardo, A. P. Yates, S. A. Roberts, P. Pemberton, and I. Laing The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome
Hum. Reprod.,
November 1, 2009;
24(11):
2917 - 2923.
[Abstract][Full Text][PDF]
R. Homburg Androgen circle of polycystic ovary syndrome
Hum. Reprod.,
July 1, 2009;
24(7):
1548 - 1555.
[Abstract][Full Text][PDF]
J. Hirshfeld-Cytron, R. B. Barnes, D. A. Ehrmann, A. Caruso, M. M. Mortensen, and R. L. Rosenfield Characterization of Functionally Typical and Atypical Types of Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
May 1, 2009;
94(5):
1587 - 1594.
[Abstract][Full Text][PDF]
A. Piouka, D. Farmakiotis, I. Katsikis, D. Macut, S. Gerou, and D. Panidis Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels
Am J Physiol Endocrinol Metab,
February 1, 2009;
296(2):
E238 - E243.
[Abstract][Full Text][PDF]
D. M. Robertson, G. E. Hale, D. Jolley, I. S. Fraser, C. L. Hughes, and H. G. Burger Interrelationships between Ovarian and Pituitary Hormones in Ovulatory Menstrual Cycles across Reproductive Age
J. Clin. Endocrinol. Metab.,
January 1, 2009;
94(1):
138 - 144.
[Abstract][Full Text][PDF]
P. Da Silva-Buttkus, G. S. Jayasooriya, J. M. Mora, M. Mobberley, T. A. Ryder, M. Baithun, J. Stark, S. Franks, and K. Hardy Effect of cell shape and packing density on granulosa cell proliferation and formation of multiple layers during early follicle development in the ovary
J. Cell Sci.,
December 1, 2008;
121(23):
3890 - 3900.
[Abstract][Full Text][PDF]
A I Qureshi, S S Nussey, G Bano, P Musonda, S A Whitehead, and H D Mason Testosterone selectively increases primary follicles in ovarian cortex grafted onto embryonic chick membranes: relevance to polycystic ovaries
Reproduction,
August 1, 2008;
136(2):
187 - 194.
[Abstract][Full Text][PDF]
S. Franks, J. Stark, and K. Hardy Follicle dynamics and anovulation in polycystic ovary syndrome
Hum. Reprod. Update,
May 22, 2008;
(2008)
dmn015v1.
[Abstract][Full Text][PDF]
P.A Johnson, T.R Kent, M.E Urick, and J.R Giles Expression and Regulation of Anti-Mullerian Hormone in an Oviparous Species, the Hen
Biol Reprod,
January 1, 2008;
78(1):
13 - 19.
[Abstract][Full Text][PDF]
S. A. Stubbs, J. Stark, S. M. Dilworth, S. Franks, and K. Hardy Abnormal Preantral Folliculogenesis in Polycystic Ovaries Is Associated with Increased Granulosa Cell Division
J. Clin. Endocrinol. Metab.,
November 1, 2007;
92(11):
4418 - 4426.
[Abstract][Full Text][PDF]
D. S. Wachs, M. S. Coffler, P. J. Malcom, and R. J. Chang Serum Anti-Mullerian Hormone Concentrations Are Not Altered by Acute Administration of Follicle Stimulating Hormone in Polycystic Ovary Syndrome and Normal Women
J. Clin. Endocrinol. Metab.,
May 1, 2007;
92(5):
1871 - 1874.
[Abstract][Full Text][PDF]
L. J. Webber, S. A. Stubbs, J. Stark, R. A. Margara, G. H. Trew, S. A. Lavery, K. Hardy, and S. Franks Prolonged Survival in Culture of Preantral Follicles from Polycystic Ovaries
J. Clin. Endocrinol. Metab.,
May 1, 2007;
92(5):
1975 - 1978.
[Abstract][Full Text][PDF]
F. H. Thomas, E. E. Telfer, and H. M. Fraser Expression of Anti-Mullerian Hormone Protein during Early Follicular Development in the Primate Ovary in Vivo Is Influenced by Suppression of Gonadotropin Secretion and Inhibition of Vascular Endothelial Growth Factor
Endocrinology,
May 1, 2007;
148(5):
2273 - 2281.
[Abstract][Full Text][PDF]
R. L. Rosenfield Identifying Children at Risk for Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
March 1, 2007;
92(3):
787 - 796.
[Abstract][Full Text][PDF]
S. Rice, K. Ojha, S. Whitehead, and H. Mason Stage-Specific Expression of Androgen Receptor, Follicle-Stimulating Hormone Receptor, and Anti-Mullerian Hormone Type II Receptor in Single, Isolated, Human Preantral Follicles: Relevance to Polycystic Ovaries
J. Clin. Endocrinol. Metab.,
March 1, 2007;
92(3):
1034 - 1040.
[Abstract][Full Text][PDF]
G. Meduri, N. Massin, J. Guibourdenche, A. Bachelot, O. Fiori, F. Kuttenn, M. Misrahi, and P. Touraine Serum anti-Mullerian hormone expression in women with premature ovarian failure
Hum. Reprod.,
January 1, 2007;
22(1):
117 - 123.
[Abstract][Full Text][PDF]
D. Modi, D. Bhartiya, and C. Puri Developmental expression and cellular distribution of Mullerian inhibiting substance in the primate ovary.
Reproduction,
September 1, 2006;
132(3):
443 - 453.
[Abstract][Full Text][PDF]
T. Sir-Petermann, E. Codner, M. Maliqueo, B. Echiburu, C. Hitschfeld, N. Crisosto, F. Perez-Bravo, S. E. Recabarren, and F. Cassorla Increased Anti-Mullerian Hormone Serum Concentrations in Prepubertal Daughters of Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
August 1, 2006;
91(8):
3105 - 3109.
[Abstract][Full Text][PDF]